Cilostazol #33528
Product Information
Product Usage Information
Storage
Product Description
| Molecular Weight | 369.5 g/mol |
| Purity | >98% |
| Molecular Formula | C20H27N5O2 |
| CAS | 73963-72-1 |
| Solubility | Soluble in DMSO at 20 mg/mL. |
Background
Cilostazol is a potent inhibitor (IC50 = 0.57 μM) of phosphodiesterase 3 (PDE3) and also inhibits the uptake of adenosine into muscle, endothelial cells, erythrocytes, and platelets (1). PDE3 hydrolyses both cAMP and cGMP, and plays a role in regulating cAMP-mediated signaling in a number of cell and tissue types, but is particularly important in regulating heart muscle, vascular smooth muscle, and platelet aggregation (2). Clinical studies demonstrate that Cilostazol is effective against inflammation, insulin resistance, and cardiomyopathy. Cilostazol, in conjunction with anti-platelet medication, reduced risk of restenosis, amputation, and target lesion revascularization following peripheral vascular interventions (3). Treatment of a murine model of obesity-associated left ventricular diastolic dysfunction with Cilostazol and hypertension medication resulted in improved left ventricular function and reduced TGF-β1/SMAD3 and Akt/mTOR signaling (4). Cilostazol is seen as more effective than aspirin in preventing recurrent ischemic stroke and intracranial hemorrhage (5), and as a potential treatment of Raynaud syndrome (6).
- Liu, Y. et al. (2001) Cardiovasc Drug Rev 19, 369-86.
- Movsesian, M. et al. (2018) J Cardiovasc Dev Dis 5, 10. doi: 10.3390/jcdd5010010.
- Warner, C.J. et al. (2014) J Vasc Surg 59, 1607-14.
- Reddy, S.S. et al. (2018) J Mol Cell Cardiol 123, 46-57.
- Lin, M.P. et al. (2021) J Stroke Cerebrovasc Dis 30, 105581.
- El-Hachem, N. et al. (2021) Curr Med Chem 28, 2409-2417.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.